ReviewHepatology communications2020
Chronic Viral Hepatitis: Current Management and Future Directions.
Review in Hepatology communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- The Neuroimmunome of Hepatitis Patients Associates With Disease Severity.Journal of medical virology · 2025Pooled it
- B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection.Advances in therapy · 2023Trial
- Liver sinusoidal endothelial cells in liver diseases and hepatocellular carcinoma: molecular mechanisms, physiology, and therapies.Molecular biomedicine · 2026Review
- Metabolic dysfunction-associated steatohepatitis is the leading indication for adult liver transplantation in Saudi Arabia.PloS one · 2025Article
- Physiomimetic In Vitro Human Models for Viral Infection in the Liver.Seminars in liver disease · 2023Review
- Preclinical Long-term Magnetic Resonance Imaging Study of Silymarin Liver-protective Effects.Journal of clinical and translational hepatology · 2022Article
- Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.World journal of gastroenterology · 2022Article
- Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers.Hepatology international · 2022Article
- Viral hepatitis in 2021: The challenges remaining and how we should tackle them.World journal of gastroenterology · 2022Review
- Present and future management of viral hepatitis.World journal of gastroenterology · 2021Review
- Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome.Journal of viral hepatitis · 2021Article
- Review
- Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections.Biological trace element research · 2021Review
- Role of liver sinusoidal endothelial cells in liver diseases.Nature reviews. Gastroenterology & hepatology · 2021Review
- Systemic pharmacology understanding of the key mechanism of Sedum sarmentosum Bunge in treating hepatitis.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Anno 2021: Which antivirals for the coming decade?Annual reports in medicinal chemistry · 2021Article
- Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs.The Enzymes · 2021Article
- Cellular Mechanisms of Liver Fibrosis.Frontiers in pharmacology · 2021Review
- Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy.Microorganisms · 2020Article
- Targeting Viral cccDNA for Cure of Chronic Hepatitis B.Current hepatology reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The past decade has seen transformation in the strategies for identifying and managing viral hepatitis, most dramatically the transformation of hepatitis C virus from a mostly chronic affliction to a curable disease that is accessible to wide populations through direct-acting antiviral therapies. More recently, shifting of hepatitis C virus burden to younger patients driven by intravenous drug use has shaped screening recommendations. Future work focusing on effective screening, linkage to care, treatment initiation, and post-cure management will allow countries to work toward meeting goals of eliminating viral hepatitis as a major public health threat. Concurrently, hepatitis B virus has also seen advances in management using oral nucleos(t)ide therapies with high-resistance barriers. However, virologic cure remains elusive in the setting of viral genetic persistence within the hepatocyte nucleus, even with suppressive antiviral therapy. Future directions include a refined definition of "cure," new biomarkers, and development of therapies targeting multiple pathways in the viral pathogenic and replication pathway. Progress is additionally being made on the management of hepatitis D infection. This review summarizes the recent evolution in disease characteristics, associated affected population, and changes in our understanding of management for these infections. We also discuss future directions in the management of viral hepatitis, including discussion on issues related to management before and after antiviral therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.